Search
Aminophylline
go.drugbank.com/drugs/DB01223ApprovedInvestigationalThe majority of aminophylline medications are discontinued and the remaining medications on the market are in short supply. … Aminophylline is a drug combination that contains theophylline and ethylenediamine in a 2:1 ratio.
Categories: Compounds used in a research, industrial, or household settingPemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigational[A193719] FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast … [A193716] In April 2020, pemigatinib was approved by the FDA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously treated adult patients with a fibroblast
Antithrombin Alfa
go.drugbank.com/drugs/DB11166ApprovedAntithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations
Alirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalAlirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of … The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. PCSK9 inhibition facilitates more LDL-C clearance from the blood.
Products: PRALUENT 150 MG/ML (SOLUTION FOR INJECTION IN PRE-FILLED PEN), PRALUENT 75 MG/ML (SOLUTION FOR INJECTION IN PRE-FILLED PEN)Iodamide
go.drugbank.com/drugs/DB08948ApprovedWithdrawnIodamide is a contrast medium molecule that is no longer marketed in the United States.
Categories: Compounds used in a research, industrial, or household settingHuman cord blood hematopoietic progenitor cell
go.drugbank.com/drugs/DB11054ApprovedAfter the first cord blood transplant in 1988 in a patient with Fanconi anemia [A32220], the use of umbilical cord blood transplantation was increased in clinical settings. … Hemacord is marketed in the U.S. as an allogeneic cord blood hematopoietic progenitor cell therapy for intravenous use.
Osimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalIn contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. … [A7927] More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy.
Synonyms: N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamideSutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigational[A245154] Notably, none of these agents are approved for use in the treatment of CAD. … [L40114,A245144] Sutimlimab was also approved by the European Commission in November 2022.[L44116]
Ribociclib
go.drugbank.com/drugs/DB11730ApprovedInvestigationalRibociclib was approved by the FDA in March 2017 under the brand name Kisqali.
Agomelatine
go.drugbank.com/drugs/DB06594ApprovedInvestigationalIn 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011. … Agomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005.